Title: Effects of CYP Induction by Rifampicin on Tamoxifen Exposure
Abstract: Clinical Pharmacology & TherapeuticsVolume 92, Issue 1 p. 62-67 Reports Effects of CYP Induction by Rifampicin on Tamoxifen Exposure L Binkhorst, Corresponding Author L Binkhorst [email protected] Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorT van Gelder, T van Gelder Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorW J Loos, W J Loos Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorF E de Jongh, F E de Jongh Department of Internal Medicine, Ikazia Hospital, Rotterdam, The NetherlandsSearch for more papers by this authorP Hamberg, P Hamberg Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, The NetherlandsSearch for more papers by this authorI M Ghobadi Moghaddam-Helmantel, I M Ghobadi Moghaddam-Helmantel Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorE de Jonge, E de Jonge Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorA Jager, A Jager Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorC Seynaeve, C Seynaeve Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorR H N van Schaik, R H N van Schaik Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorJ Verweij, J Verweij Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorR H J Mathijssen, R H J Mathijssen Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this author L Binkhorst, Corresponding Author L Binkhorst [email protected] Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorT van Gelder, T van Gelder Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorW J Loos, W J Loos Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorF E de Jongh, F E de Jongh Department of Internal Medicine, Ikazia Hospital, Rotterdam, The NetherlandsSearch for more papers by this authorP Hamberg, P Hamberg Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, The NetherlandsSearch for more papers by this authorI M Ghobadi Moghaddam-Helmantel, I M Ghobadi Moghaddam-Helmantel Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorE de Jonge, E de Jonge Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorA Jager, A Jager Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorC Seynaeve, C Seynaeve Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorR H N van Schaik, R H N van Schaik Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorJ Verweij, J Verweij Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorR H J Mathijssen, R H J Mathijssen Department of Medical Oncology, Erasmus MC—Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this author First published: 23 May 2012 https://doi.org/10.1038/clpt.2011.372Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Tamoxifen undergoes biotransformation into several metabolites, including endoxifen. Differences in metabolism contribute to the interindividual variability in endoxifen concentrations, potentially affecting treatment efficacy. We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P ≤ 0.040) concentrations of tamoxifen and its metabolites. Given the extensive metabolism undergone by tamoxifen, several factors may have contributed to this effect. Similar drug–drug interactions may exist between tamoxifen and other strong CYP inducers. Clinical Pharmacology & Therapeutics (2012); 92 1, 62–67. doi:10.1038/clpt.2011.372 Citing Literature Supporting Information Filename Description cptclpt2011372-sup-0001.docapplication/doc, 136.5 KB Supplementary Figure S1 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume92, Issue1Quantitative ModelsJuly 2012Pages 62-67 RelatedInformation
Publication Year: 2012
Publication Date: 2012-05-23
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 36
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot